Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Qinlock (ripretinib) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Ripretinib demonstrated the highest effectiveness among third-line or beyond therapies for gastrointestinal stromal tumors (GIST), with superior progression-free survival (PFS), overall survival (OS), and disease control rate (DCR) compared to other drugs, supported by SUCRA statistics of 83.1%, 82.5%, and 86.5%, respectively.
• Ripretinib significantly improved PFS and OS compared to placebo, imatinib, and sunitinib in Phase II or III randomized controlled trials (RCTs), with hazard ratios (HR) for PFS ranging from 0.15 to 0.44, and for OS from 0.18 to 0.36.
• Treatment with ripretinib, imatinib, and regorafenib maintained health-related quality of life (HRQoL), with sunitinib being the only drug associated with a decrease in HRQoL.
• Nearly all GIST patients experienced at least one adverse event, predominantly mild to moderate, with severe fatigue and fear of recurrence/progression negatively impacting HRQoL; these side effects did not significantly affect overall HRQoL and were possibly underestimated by physicians.
• Ripretinib had lower tolerability compared to nilotinib and pimitespib, while regorafenib was associated with the highest rates of high-grade adverse events; ripretinib and masitinib demonstrated the lowest rates of severe adverse events.
• There is no population types or subgroups information available in the reviewed studies.